OVERVIEW

Follistatin-315 1 mg refers to a specific isoform of follistatin, a naturally occurring glycoprotein that binds and inhibits members of the transforming growth factor-beta (TGF-β) superfamily, especially myostatin and activins, which are key regulators of muscle growth and tissue remodeling. Follistatin-315 is the longest of the major human follistatin isoforms, distinguished by an extended C-terminal sequence that influences its biodistribution and interaction with circulating ligands. In preclinical research, increased levels of follistatin-315 have been associated with enhanced muscle fiber growth and reduced myostatin signaling in animal models, leading to interest in its role in muscle hypertrophy, regeneration, and recovery following injury. Because myostatin acts as a negative regulator of muscle mass, inhibiting it through follistatin-315 in experimental systems can amplify anabolic signaling pathways and has made this peptide a focus of regenerative biology and performance-related research.

Despite these experimental observations, Follistatin-315 1 mg is not approved by the U.S. Food and Drug Administration for therapeutic use in humans or for muscle-enhancing purposes, and robust clinical evidence supporting its safety and efficacy is lacking. Most available data arise from animal studies or controlled laboratory models rather than well-controlled human trials, and the long-term effects of modulating TGF-β pathways systemically remain uncertain. Products marketed with follistatin-315 are typically sold as research chemicals and are not regulated to pharmaceutical quality standards, meaning purity and dosing consistency can vary widely. Use outside of authorized research environments carries potential safety, ethical, and legal risks, and individuals interested in muscle growth, recovery, or metabolic health should seek advice from qualified healthcare professionals and rely on established, evidence-based interventions.